Coverage of Duke University’s licensing of the Pompe disease gene-editing technology to GeneVentiv.
Duke University covered its exclusive license with GeneVentiv to commercialize GENV-002, a gene-editing therapy developed in the laboratory of Dwight Koeberl for infantile-onset and late-onset Pompe disease.